Our innovative sustained-release micro technology
THE UNMET NEED OF NEW DRUG DELIVERY SYSTEMS
At the moment, many diseases affecting very small parts of the human body still depend solely on systemic treatments. In other words, these treatments rely on the administration of drugs that must circulate throughout the body to reach the organ to be treated, namely a part of the body that is very difficult to reach, like the eye, ear, brain, or even a tumor…
Because these treatments are systemic, the therapeutic doses they use are often heavy and the administration must be frequent, resulting in numerous side effects affecting patients’ daily lives. And because they are generally self-administered, patient compliance is often poor.
The innovation challenge
HOW TO INNOVATE?
Our challenge was clear. How to offer a local treatment that would act directly on the site of action with very small doses of the drug, thus drastically limiting side effects and guaranteeing 100% patient compliance, even in the most complicated and hard-to-reach parts of the body?
That’s where we came in with innovative sustained-release polymer-based micro-implants.
Why micro-implants?
AN INNOVATIVE DRUG DELIVERY SYSTEM
Our polymer micro-implants enable a highly precise, local, non-systemic delivery of a drug directly on the site of action where the pathology is expressed, releasing sustained micro-quantities of API over time, from a few days to 9 years.
Our innovative solutions could not only considerably reduce treatment side effects and drastically improve patients’ daily quality of life, but also ensure 100% patient compliance.
Eye health is key to ensuring good health, mental health, and overall well-being.
WHY OPHTHALMOLOGY?
Today, 1.1 billion people are living with vision loss due to eye diseases. And most existing treatments for eye pathologies are systemic (mostly eye drops) and often involve numerous side effects affecting patients’ daily lives.
We decided to rise to the challenge by developing a R&D portfolio of ocular micro-implants designed to provide new forms of treatment for eye diseases such as glaucoma, dry eye and pathologies at the back of the eye (diabetic macular edema (DME), posterior uveitis).
